We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.
Home Carousel
FACIT Announces Six Finalists for 2021 Falcons' Fortunes Pitch Competition
This year's virtual pitch competition showcases six Ontario-based entrepreneurial researchers working in the oncology space to pitch their innovative research ideas to a panel of judges.
The 8th annual Falcons’ Fortunes competition will be held virtually on Thursday, February 4th, 2021.
FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund
Ontario First capital supports early stage commercialization of cancer intellectual property
The newest recipients of Ontario First seed capital include Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc.
FACIT Features: Triphase Accelerator reports positive interim results of lead compound in Phase 1 Clinical Trial for Lymphoma
The encouraging study results includes six complete remissions in previously-treated lymphoma patients.
FACIT congratulates Triphase Accelerator on interim results from its ongoing Phase 1 multi-center, open-label monotherapy study of TRPH-222.
FACIT Features: DNAstack to lead and develop COVID Cloud for Canada’s Digital Technology Supercluster
The COVID Cloud will enable accelerated and more insightful interpretation of COVID-19, leading to increased preparedness for future outbreaks, and identification of potential treatments.
FACIT is pleased to accept the invitation to join the national consortium as Lead Commercialization Advisor.
FACIT Features: Portfolio company KA Imaging secures FDA approval for portable dual-energy x-ray detector
Reveal™ enables bone and soft tissue differentiation in a single, highly sensitive x-ray exposure.
Since FACIT’s early seed investment in KA Imaging, the company has greatly expanded its IP portfolio, as well as the number of highly skilled jobs it has brought to Ontario.
FACIT congratulates Fusion Pharma on its Initial Public Offering
Following other successful Canadian biotech IPOs this year, Fusion’s IPO represents the largest by an Ontario biotechnology company
FACIT congratulates Hamilton-based Fusion Pharma (NASDAQ: FUSN) on its initial public offering (IPO) with shares of the company beginning to trade on the Nasdaq Global Market exchange today.
as of July 2020
-
$1.2B
Leveraged funding associated with FACIT support.
-
$43M
Funding & equity investments.
-
59
Projects at Ontario institutions or Startups supported by FACIT funding.
-
16
Companies in Ontario created by FACIT investments.
Our Strategic Partner
FACIT also facilitates technology transfer, partnerships, and collaborations with the
Ontario Institute for Cancer Research >
